Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1954 2
1955 1
1975 1
1978 1
1983 1
1984 1
1994 1
1995 2
1999 1
2000 1
2004 2
2005 2
2007 3
2008 1
2009 2
2010 5
2011 4
2012 4
2013 3
2014 2
2016 7
2017 7
2018 6
2020 3
2021 3
2022 2
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Pfisterer J, et al. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Lancet Oncol. 2020. PMID: 32305099 Clinical Trial.
Targeting homologous recombination deficiency in uterine leiomyosarcoma.
Dall G, Vandenberg CJ, Nesic K, Ratnayake G, Zhu W, Vissers JHA, Bedő J, Penington J, Wakefield MJ, Kee D, Carmagnac A, Lim R, Shield-Artin K, Milesi B, Lobley A, Kyran EL, O'Grady E, Tram J, Zhou W, Nugawela D, Stewart KP, Caldwell R, Papadopoulos L, Ng AP, Dobrovic A, Fox SB, McNally O, Power JD, Meniawy T, Tan TH, Collins IM, Klein O, Barnett S, Olesen I, Hamilton A, Hofmann O, Grimmond S, Papenfuss AT, Scott CL, Barker HE. Dall G, et al. Among authors: olesen i. J Exp Clin Cancer Res. 2023 May 4;42(1):112. doi: 10.1186/s13046-023-02687-0. J Exp Clin Cancer Res. 2023. PMID: 37143137 Free PMC article.
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Nesic K, Krais JJ, Vandenberg CJ, Wang Y, Patel P, Cai KQ, Kwan T, Lieschke E, Ho GY, Barker HE, Bedo J, Casadei S, Farrell A, Radke M, Shield-Artin K, Penington JS, Geissler F, Kyran E, Zhang F, Dobrovic A, Olesen I, Kristeleit R, Oza A, Ratnayake G, Traficante N; Australian Ovarian Cancer Study; DeFazio A, Bowtell DDL, Harding TC, Lin K, Swisher EM, Kondrashova O, Scott CL, Johnson N, Wakefield MJ. Nesic K, et al. Among authors: olesen i. medRxiv [Preprint]. 2023 Aug 28:2023.03.20.23287465. doi: 10.1101/2023.03.20.23287465. medRxiv. 2023. PMID: 36993400 Free PMC article. Preprint.
Environment, testicular dysgenesis and carcinoma in situ testis.
Olesen IA, Sonne SB, Hoei-Hansen CE, Rajpert-De Meyts E, Skakkebaek NE. Olesen IA, et al. Best Pract Res Clin Endocrinol Metab. 2007 Sep;21(3):462-78. doi: 10.1016/j.beem.2007.04.002. Best Pract Res Clin Endocrinol Metab. 2007. PMID: 17875492 Review.
Public health restrictions, directives, and measures in Arctic countries in the first year of the COVID-19 pandemic.
Peterson M, Akearok GH, Cueva K, Lavoie JG, Larsen CV, Jóhannsdóttir L, Cook D, Nilsson LM, Rautio A, Timlin U, San Sebastián M, Gladun E, Rink E, Broderstadt AR, Dagsvold I, Siri S, Ottendahl CB, Olesen I, Zatseva L, Young RI, Chaliak AJ, Ophus E, Stoor JPA. Peterson M, et al. Among authors: olesen i. Int J Circumpolar Health. 2023 Dec;82(1):2271211. doi: 10.1080/22423982.2023.2271211. Epub 2023 Oct 29. Int J Circumpolar Health. 2023. PMID: 37898999 Free PMC article. Review.
Current approaches for detection of carcinoma in situ testis.
Hoei-Hansen CE, Olesen IA, Jorgensen N, Carlsen E, Holm M, Almstrup K, Leffers H, Rajpert-De Meyts E. Hoei-Hansen CE, et al. Among authors: olesen ia. Int J Androl. 2007 Aug;30(4):398-404; discussion 404-5. doi: 10.1111/j.1365-2605.2007.00797.x. Int J Androl. 2007. PMID: 17705812 Review.
Testicular dysgenesis syndrome and the origin of carcinoma in situ testis.
Sonne SB, Kristensen DM, Novotny GW, Olesen IA, Nielsen JE, Skakkebaek NE, Rajpert-De Meyts E, Leffers H. Sonne SB, et al. Among authors: olesen ia. Int J Androl. 2008 Apr;31(2):275-87. doi: 10.1111/j.1365-2605.2007.00855.x. Epub 2008 Jan 16. Int J Androl. 2008. PMID: 18205797 Review.
The Greenland population health survey 2018 - methods of a prospective study of risk factors for lifestyle related diseases and social determinants of health amongst Inuit.
Bjerregaard P, Larsen CVL, Olesen I, Ottendahl CB, Backer V, Senftleber N, Christensen MMB, Larsen TJ, Byberg S, Hansen T, Jørgensen ME. Bjerregaard P, et al. Among authors: olesen i. Int J Circumpolar Health. 2022 Dec;81(1):2090067. doi: 10.1080/22423982.2022.2090067. Int J Circumpolar Health. 2022. PMID: 35711125 Free PMC article.
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.
Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Ghamsari MRE, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Australian Ovarian Cancer Study, DeFazio A, Bowtell DDL, Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A, Wakefield MJ, Scott CL. Nesic K, et al. Among authors: olesen i. Cancer Res. 2021 Sep 15;81(18):4709-4722. doi: 10.1158/0008-5472.CAN-21-0774. Epub 2021 Jul 28. Cancer Res. 2021. PMID: 34321239
70 results